Abbvie Inc ABBV

$284.80 -4.28 (-1.48%)

Valuation

Market cap
499,437,056,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
PE ratio
26.26
Forward PE
20.48
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
4,394,500
Avg volume
4,608,324
Day's range
$282.15 – $289.00
Shares out
1,766,793,000
Stochastic %K
91%
Beta
0.24
Analysts
Strong Sell
Price target
$282.37

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

SellasgpsCurativeBAT11 Oct 21, 11:20 PM
$SLS $JNJ $AZN $PFE $ABBV Sellas has Booth than Seagen= $50 Billy. Keep it simple. Like they say keep it simple stupid. We will skip moon on this trip! ✌️🙏❤️‍🩹
0 replies
55X_ROI_Q1_2026 Oct 21, 10:34 PM
$SLS $2.3B about to be $25B and Climbing $ABBV https://youtu.be/nCtrZavKCuM?si=k-5PejP6ZTGIckg0&t=1581 Dr. Omer Jamy - one of the Largest US Enrolling REGAL Clinicians. He treats actual Phase 3 Patients -- literally says it -- BAT MOS is Just 6-8 months - Gps P2 was 21 months - I Treat these Patients.... If you like Money --- DD - SLS is the NEXT $MRNA from $22 Per Share to a High of $252 Per Share TODAY -- + $90B in Market Value ALL based on Phase 3 Cancer vaccine data similar to What SLS will be Announcing ANY DAY NOW. Direct Link to Dr. Jamy Detailing the Current SOC/BAT AML Patients. https://youtu.be/nCtrZavKCuM?si=k-5PejP6ZTGIckg0&t=1581
0 replies
55X_ROI_Q1_2026 Oct 21, 9:04 PM
$SLS $MRNA we are Now + 10 Months Later than ANTICIPATED . https://youtu.be/nCtrZavKCuM?si=QLzDdHp26qF-fiJZ&t=751 Direct Link: “ should that event occur later than anticipated, from a mathematical standpoint, and the fact we administer GPs even three years out, every passing month may increase the probability of a successful study due to a Potential Gps Effect as we have seen in our previous CR1 and CR2 Studies far surpassing median overall survival vs standard of care - when the 80th event arises, we will inform the public…” “ We expect 80th event by year end, but its an event driven study, blinded to outcomes survival times appear unexpectedly long, due to significantly longer than expected survival, the timing of final analysis difficult to predict w any certainty and the 80th event may occur at a different time than currently expected.” $MRNA $ABBV
0 replies
Quantumup Oct 21, 8:29 PM
TD Cowen⬆️ $ROIV's PT to $62 from $55 and reiterated Buy after what they called spectacular Phase 3 data for brepocitinib in non-infectious uveitis (NIU). $PFE $ABBV BMY LLY TD Cowen said that after the unequivocally positive and potentially paradigm-shifting data, they raised their view of NIU odds of success to 100% and now model about $3B in global NIU sales and overall global brepocitinib sales of $6.1B by FY33.
0 replies
55X_ROI_Q1_2026 Oct 21, 6:57 PM
$SLS $ABBV $BMY 202M SLS Shares Outstanding 202M/ $50B Mcap $247 Per SLS Share Gps has a $28B Total Addressable Market and will set Records for Patient Uptake rates w 2x 4X OS benefits, pristine safety profile, ease of manufacture, storage and Administration. Ip rights into 2037, FDA EU Orphan and Fast Track Designations. Phase 3 Registrational Results w Miraculous Survival Data will be Announced Any Day Now. $MRNA and MRK added $80B in Market Value in the Days after thier Cancer Vaccine results were announced. Something Very Similar is about to Happen Here.
0 replies
55X_ROI_Q1_2026 Oct 21, 6:03 PM
$SLS Very Likely Big Pharma will be Buying $MRNA for +$300 per share and SLS for +$200 per share. Big Pharma's Staring into the Abyss over the Patent Cliffs - Desperate for Replacement Revenue. Occam's Razor - these 2 Bio's with Green Lights to Generate Tens of BIllions will be Bought AFTER a Bidding War. $LLY $ABBV $PFE ...
0 replies
55X_ROI_Q1_2026 Oct 21, 4:52 PM
$SLS While we await, Imminent Miraculous GPS Phase 3 Trial Results, - Gps has proven effective in preventing relapse and extending survival in all prior trials, INCLUDING 2 Phase 2 Trials for AML Remission Maintenance --- - and BAT for Control Arm Patients has FAILED to Increase Survival in 5 RECENT AML Trials... including Failing 2 Phase 3 Trials $ABBV for AML Remission Maintenance. it is Not Complicated. /
0 replies
55X_ROI_Q1_2026 Oct 21, 4:24 PM
$SLS we are Now + 10 Months Later than ANTICIPATED “ should that even occur later than anticipated, from a mathematical standpoint, and the fact we administer GPs even three years out, every passing month may increase the probability of a successful study due to a Potential Gps Effect as we have seen in our previous CR1 and CR2 Studies far surpassing median overall survival vs standard of care - when the 80th event arises, we will inform the public…” “ We expect 80th event by year end, but its an event driven study, blinded to outcomes survival times appear unexpectedly long, due to significantly longer than expected survival, the timing of final analysis difficult to predict w any certainty and the 80th event may occur at a different time than currently expected.” $MRNA $ABBV
0 replies